Metabolic syndrome (MetS) is a complex clinical syndrome characterized by obesity, hypertension, hyperglycemia, dyslipidemia, and other metabolic abnormalities. Insulin resistance is the central feature of this syndrome. Irrespective of the specific definition of MetS, its occurrence is on the rise globally. In countries where obesity rates are high and dietary habits are unhealthy, MetS has become a prevalent medical condition and a major public health concern, resulting in substantial economic burdens. Research has shown that MetS is associated with an elevated risk of bladder cancer. Additionally, individuals with MetS tend to have bladder cancer that is more advanced in terms of pathological grade and stage. There is a scarcity of evidence about the correlation between bladder cancer patients with MetS and their oncological outcomes, such as death, overall survival, cancer-specific survival, disease recurrence, and disease progression. We plan to utilize various data sources, including the UK Biobank and the Alpha Omega cohort, to conduct a more comprehensive analysis of these connections. The aim of our study was to thoroughly assess the association between each metabolic component of Metabolic Syndrome (e.g., obesity, diabetes) and the likelihood of developing bladder cancer or experiencing oncologic outcomes. Specifically, we also aim to examine whether the collective impact of MetS is higher or lesser than the single effect of its individual metabolic components. Our results are expected to provide a theoretical basis for the prevention, diagnosis and treatment of bladder cancer.
